Enhancing the Oral Bioavailability of Poorly Water Soluble BCS Class IV Drug Docetaxel Using Mesoporous Silica Nanoparticles

This study involves the use of mesoporous silica to evaluate the in vivo performance of ordered mesoporous silica (OMS) as a carrier for poorly water soluble drugs. Mesoporous silica is selected as a carrier for poorly water-soluble drug. Docetaxel is selected as model compound. Solid dispersion technology was used to prepare the Docetaxel loaded mesoporous silica nanoparticles. Physicochemical characterization was carried out by SEM, IR, DSC, and PXRD. Percent drug release was calculated by in vitro dissolution. Because in vitro dissolution is directly correlated with bioavailability in pharmaceutical research, an emerging approach to enhance dissolution is encapsulation of hydrophobic amorphous drugs in ordered mesoporous silica materials. The outstanding features of ordered mesoporous silica materials, including their highly regular mesoporous structure, high surface area, large pore volume, tunable pore size, good biocompatibility, and thermal stability have led to these materials becoming important drug carriers. This work concluded that PARTECK SILICA SLC can therefore be considered as a promising carrier to achieve enhanced oral bioavailability for drugs with extremely low water solubility.